Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated IκB kinase

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 2, 2009, Pages 173-179

  Von Metzler, Ivana ^a   Krebbel, Holger ^a   Kuckelkorn, Ulrike ^a   Heider, Ulrike ^a   Jakob, Christian ^a   Kaiser, Martin ^a   Fleissner, Claudia ^a   Terpos, Evangelos ^b   Sezer, Orhan ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b 251 GENERAL AIR FORCE HOSPITAL   (Greece)

Author keywords

Cancer; Curcumin; I B; NF B; Osteoclast; Proteasome

Indexed keywords

ANTINEOPLASTIC AGENT; CURCUMIN; I KAPPA B KINASE; TRANSCRIPTION FACTOR;

ARTICLE; BONE DISEASE; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; NEOPLASM; OSTEOCLAST; OSTEOLYSIS; PATHOLOGY; REFERENCE VALUE;

ANTINEOPLASTIC AGENTS; BONE DISEASES; BONE RESORPTION; CELL DIFFERENTIATION; CELL SURVIVAL; CURCUMIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; I-KAPPA B KINASE; NEOPLASMS; OSTEOCLASTS; REFERENCE VALUES; TRANSCRIPTION FACTORS;

EID: 63849150893     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-008-0461-8     Document Type: Article

References (43)

1. Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S et al (2002) Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100:2195-2202
2. Akatsu T, Takahashi N, Udagawa N, Sato K, Nagata N, Moseley JM et al (1989) Parathyroid hormone (PTH)-related protein is a potent stimulator of osteoclast-like multinucleated cell formation to the same extent as PTH in mouse marrow cultures. Endocrinology 125:20-27
3. Baeuerle PA, Baltimore D (1988) I kappaB: a specific inhibitor of the NF-kappaB transcription factor. Science 242:540-546. doi:10.1126/science.3140380
4. Bertolini DR, Nedwin GE, Bringman TS, Smith DD, Mundy GR (1986) Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 319:516-518. doi:10.1038/319516a0
5. Bharti AC, Takada Y, Aggarwal BB (2004) Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappaB ligand-induced NF-kappaB activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 172:5940-5947
6. Bowie A, O'Neill LA (2000) Oxidative stress and nuclear factorkappaB activation: a reassessment of the evidence in the light of recent discoveries. Biochem Pharmacol 59:13-23. doi:10.1016/S0006-2952(99)00296-8
7. Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337-342. doi:10.1038/nature01658
8. Chuang SE, Yeh PY, Lu YS, Lai GM, Liao CM, Gao M et al (2002) Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem Pharmacol 63:1709-1716. doi:10.1016/S0006-2952(02)00931-0
9. Collart MA, Baeuerle P, Vassalli P (1990) Regulation of tumor necrosis factor alpha transcription in macrophages: involvement of four kappaB-like motifs and of constitutive and inducible forms of NF-kappaB. Mol Cell Biol 10:1498-1506
10. Commandeur JN, Vermeulen NP (1996) Cytotoxicity and cytoprotective activities of natural compounds. The case of curcumin. Xenobiotica 26:667-680
11. Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P et al (2003) Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63:5438-5445
12. Freeman S (1957) Skeletal disease resulting from disturbed endocrine function or from errors in metabolism. Instr Course Lect 14:286-291
13. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S (2001) Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98:3527-3533. doi:10.1182/blood.V98.13. 3527
14. Gori F, Hofbauer LC, Dunstan CR, Spelsberg TC, Khosla S, Riggs BL (2000) The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. Endocrinology 141:4768-4776. doi:10.1210/en.141.12.4768
15. Hecht M, Heider U, Kaiser M, von Metzler I, Sterz J, Sezer O (2007) Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. Br J Haematol 138:446-458. doi:10.1111/j.1365-2141.2007.06665.x
16. Hecht M, von Metzler I, Sack K, Kaiser M, Sezer O (2008) Myeloma cell-osteoclast interaction stimulates expression of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA) through activation of p38 MAPK and STAT3. Exp Cell Res 314:1082-1093. doi:10.1016/j.yexcr.2007.10.021
17. Heider U, Langelotz C, Jakob C, Zavrski I, Fleissner C, Eucker J et al (2003) Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 9:1436-1440
18. Heider U, Fleissner C, Zavrski I, Kaiser M, Hecht M, Jakob C et al (2006) Bone markers in multiple myeloma. Eur J Cancer 42:1544-1553. doi:10.1016/j.ejca.2005.11.034
19. Henke W, Ferrell K, Bech-Otschir D, Seeger M, Schade R, Jungblut P et al (1999) Comparison of human COP9 signalsome and 26S proteasome lid'. Mol Biol Rep 26:29-34. doi:10.1023/A:1006991419464
20. Hofbauer LC, Heufelder AE (2001) Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med 79:243-253. doi:10.1007/s001090100226
21. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC et al (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid- induced osteoporosis. Endocrinology 140:4382-4389. doi:10.1210/en.140.10.4382
22. Hofbauer LC, Neubauer A, Heufelder AE (2001) Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 92:460-470. doi:10.1002/1097-0142 (20010801)92:3〈460::AID-CNCR1344〉3.0.CO;2-D
23. Jana NR, Dikshit P, Goswami A, Nukina N (2004) Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J Biol Chem 279:11680-11685. doi:10.1074/jbc.M310369200
24. Jimi E, Aoki K, Saito H, D'Acquisto F, May MJ, Nakamura I et al (2004) Selective inhibition of NF-kappaB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 10:617-624. doi:10.1038/nm1054
25. Kaiser M, Mieth M, Liebisch P, Oberländer R, Jakob C, Rademacher J et al (2008) Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 80:490-494. doi:10.1111/j.1600-0609.2008.01065.x
26. Karin M, Yamamoto Y, Wang QM (2004) The IKK NF-kappaB system: a treasure trove for drug development. Nat Rev Drug Discov 3:17-26. doi:10.1038/nrd1279
27. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S et al (1999) Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309. doi:10.1038/46303
28. Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE (1974) Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 291:1041-1046
29. Nair SP, Meghji S, Wilson M, Reddi K, White P, Henderson B (1996) Bacterially induced bone destruction: mechanisms and misconceptions. Infect Immun 64:2371-2380
30. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T (1994) The ubiquitin- proteasome pathway is required for processing the NF-kappaB1 precursor protein and the activation of NF-kappaB. Cell 78:773-785. doi:10.1016/S0092-8674(94) 90482-0
31. Seeger M, Kraft R, Ferrell K, Bech-Otschir D, Dumdey R, Schade R et al (1998) A novel protein complex involved in signal transduction possessing similarities to 26S proteasome subunits. FASEB J 12:469-478
32. Seyberth HW (1978) Prostaglandin-mediated hypercalcemia: a paraneoplastic syndrome. Klin Wochenschr 56:373-387. doi:10.1007/BF01477292
33. Sezer O, Heider U, Zavrski I, Kühne CA, Hofbauer LC (2003) RANK ligand and osteoprotegerin in myeloma bone disease. Blood 101:2094-2098. doi:10.1182/blood-2002-09-2684
34. Suda K, Woo JT, Takami M, Sexton PM, Nagai K (2002) Lipopolysaccharide supports survival and fusion of preosteoclasts independent of TNF-alpha, IL-1, and RANKL. J Cell Physiol 190:101-108. doi:10.1002/jcp.10041
35. Takahashi N, Udagawa N, Suda T (1999) A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 256:449-455. doi:10.1006/bbrc.1999.0252
36. Terpos E, Sezer O, Croucher P, Dimopoulos MA (2007a) Myeloma bone disease and proteasome inhibition therapies. Blood 110:1098-1104. doi:10.1182/blood- 2007-03-067710
37. Terpos E, Dimopoulos MA, Sezer O (2007b) The effect of novel antimyeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 21:1875-1884. doi:10.1038/sj.leu.2404843
38. Thompson DD, Seedor JG, Fisher JE, Rosenblatt M, Rodan GA (1988) Direct action of the parathyroid hormone-like human hypercalcemic factor on bone. Proc Natl Acad Sci USA 85:5673-5677. doi:10.1073/pnas.85.15.5673
39. von Metzler I, Krebbel H, Hecht M, Fleissner C, Mieth M, Kaiser M et al (2007) Bortezomib inhibits human osteoclastogenesis. Leukemia 21:2025-2034. doi:10.1038/sj.leu.2404806
40. Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B et al (2004) Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 64:2016-2023. doi:10.1158/0008-5472.CAN-03-1131
41. Zavrski I, Krebbel H, Wildemann B, Heider U, Kaiser M, Possinger K et al (2005a) Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun 333:200-205. doi:10.1016/j.bbrc.2005.05. 098
42. Zavrski I, Jakob C, Schmid P, Krebbel H, Kaiser M, Fleissner C et al (2005b) Proteasome: An emerging target for cancer therapy. Anticancer Drugs 16:475-481. doi:10.1097/00001813-200506000-00002
43. Zavrski I, Kleeberg L, Kaiser M, Fleissner C, Heider U, Sterz J et al (2007) Proteasome as an emerging therapeutic target in cancer. Curr Pharm Des 13:471-485. doi:10.2174/138161207780162908